🇺🇸 FDA
Pipeline program

low-dose rivaroxaban

NCRC2022002

Approved small_molecule active

Quick answer

low-dose rivaroxaban for Atrial Fibrillation is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Atrial Fibrillation
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials